Cancer
01 Jan 2013
Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema
The purpose of this study is to assess the efficacy and safety of Icatibant, a bradykinin antagonist in the treatment of acute cutaneous and/or abdominal attacks in patients with hereditary angioedema (HAE). Official Title Randomised, Double Blind, Placebo-Controlled, Multicenter Study of a Subcutaneous Formulation of Icatibant for the Treatment of…
Cancer
01 Jan 2013
Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer
RATIONALE: Collecting samples of blood and tissue from patients with cancer to study in the laboratory may help doctors learn how fluvastatin effects biomarkers related to breast cancer.PURPOSE: This randomised phase II trial is studying how fluvastatin effects biomarkers in women undergoing surgery for ductal carcinoma in situ or stage…
Cancer
01 Jan 2013
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
The main purpose of this study is to determine if AZD0530 can improve the efficacy of standard chemotherapy for the treatment of ovarian cancer. Official Title A Phase II, Double-Blind, Placebo-Controlled, Multi-Centre, Randomised Study of AZD0530 in Patients With Advanced Ovarian Cancer Sensitive to Platinum-Based Chemotherapy. Conditions Ovarian Neoplasms…
Cancer
01 Jan 2013
Bortezomib in Treating Patients With Newly Diagnosed High-Risk Stage III Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with newly diagnosed high-risk stage III multiple myeloma. Official Title Phase II Study Of PS-341 For Patients With…
Cancer
01 Jan 2013
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
The purpose of this clinical research study is to understand the safety and efficacy of BMS-354825 in patients with chronic, accelerated, or blast phase chronic myelogenous leukemia (CML) or Philadelphia positive acute lymphoblastic leukemia (ALL) who are resistant to or intolerant of imatinib mesylate (Gleevec). Official Title Phase I Study…
Cancer
01 Jan 2013
Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
Randomized phase III trial to compare the effectiveness of cisplatin plus gemcitabine with or without paclitaxel in treating patients who have stage IV urinary tract cancer. Official Title Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy…
Cancer
01 Jan 2013
Intralesional PV-10 Chemoablation of Metastatic Melanoma
The objective of this study is to investigate the safety of intralesional (IL) PV-10 for the treatment of metastatic melanoma. This study will also include a preliminary assessment of response of treated and untreated lesions by clinical evaluation at follow-up of 12 to 24 weeks following IL PV-10 treatment. Official…
Cancer
01 Jan 2013
Study of “NY-ESO-1 ISCOMATRIX” in Patients With High-Risk, Resected Melanoma
The purpose of this trial is to assess whether treatment with “NY-ESO-1 ISCOMATRIX” vaccine improves outcomes for people with Malignant Melanoma which has been removed, but is at high risk of relapse. Official Title Randomized, Double-Blind Phase II Trial of “NY-ESO-1 ISCOMATRIX” Vaccine and “ISCOMATRIX” Adjuvant Alone in Patients With…
Cancer
01 Jan 2013
A Safety Study of Two Intratumour Doses of Coxsackievirus Type A21 in Melanoma Patients.
The purpose of the study is to determine the safety and tolerability of two doses of Coxsackievirus A21, administered 48 hours apart into a superficial melanoma tumour. Injected and non-injected tumours will be observed regarding change in tumour size. Official Title A Phase I, Open Label, Cohort Study of Two…
